ZEBinix® Retention Rate in Epilepsy in Elderly Patients
ZEBinix® Retention Rate in Epilepsy in Elderly Patients
The incidence of provoked and unprovoked seizures is known to increase with advancing age.
 Eslicarbazepine acetate (ESL) is one of the third generation of antiepileptic drugs (AEDs)
 that have been developed in the last ten years with a favorable safety profile. ESL is
 approved in Europe and the USA as adjunctive or monotherapy in adults with partial-onset
 seizures. Nevertheless, retrospective data in monotherapy condition in the elderly epileptic
 population are sparse. The aim of the ZEBRE study is to evaluate the efficacy and the safety
 of ESL in elderly epileptic patients (> 65 years). The completion of this study will provide
 crucial information on the most appropriate ESL treatment for elderly patients suffering from
 partial seizures.
The ZEBRE (ZEBinix® Retention rate in epilepsy in Elderly patients) study is a prospective,
 multicenter, descriptive study. ESL will be prescribed according to the usual care. Posology
 and method of administration of ESL are defined by the summary of product characteristics.
Inclusion Criteria:

 1. Age ≥ 65 years

 2. Ability of patient/legal representative to understand the study and to give his/her
 non-opposition (at the investigator's discretion)

 3. Epilepsy with refractory partial-onset seizures with or without secondary
 generalization confirmed or with primary generalized tonic-clonic (PGTC) seizures

 4. At least one seizure in the last three months

 5. Treatment for partial-onset seizures with ESL as a first line monotherapy or with an
 adjunctive therapy

 Exclusion Criteria:

 1. History of ESL treatment

 2. History of status epilepticus, seizures occurring in cluster, pseudo-seizures

 3. History of severe hepatic impairment (aspartate aminotransferase (AST) and alanine
 aminotransferase (ALT) > 2 times ULN, gamma-glutamyltranspeptidase (GGT) > 5 times
 ULN)

 4. History of severe renal impairment (clearance CLCR <30ml/min)

 5. History of hypersensitivity to other carboxamide derivatives (e.g. carbamazepine,
 oxcarbazepine)

 6. History of severe hyponatremia (< 120 mmol/L)

 7. Second or third degree atrioventricular block

 8. More than one other antiepileptic drug